UCB (PK) Aktie - UCBJY

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

98,50

Gebot

96,93

Fragen

99,21

Volumen

30.707

97,82 Tagesbereich 98,95

56,77 52-Wochen-Bereich 106,60

Marktkapitalisierung

37,35B

Handelsende

92,80

Handelsbeginn

98,90

Letzte Trade

98.5

Letzter Handelszeitpunkt

Finanzvolumen

US$ 3.026.691

VWAP

98,5668

Durchschnittliches Volumen (3 Mio.)

36.149

Ausgegebene Aktien

379.189.796

Dividendenrendite

0.94%

Kurs-Gewinn-Verhältnis

64,44

Gewinn pro Aktie (EPS)

2,81

Erlöse

5,61B

Nettogewinn

1,07B

UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sektor

Pharmaceutical Preparations

Branche

Chemicals & Allied Products

Website

www.ucb.com

Hauptsitz

Brussels, Brussels-capital Region, Bel

Gegründet

1928

UCB (PK) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker UCBJY. The last closing price for UCB (PK) was US$92,80. Over the last year, UCB (PK) shares have traded in a share price range of US$ 56,77 to US$ 106,60.

UCB (PK) currently has 379.189.796 shares in issue. The market capitalisation of UCB (PK) is US$35,19 billion. UCB (PK) has a price to earnings ratio (PE ratio) of 64.44.

UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services

UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services Judges highlight value-added partnership and finance...

New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S.

New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S. Results of retrospective analysis...

UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015

UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015 PR Newswire ATLANTA, May 16, 2015 ATLANTA, May 16, 2015...

UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam

UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam - Major milestone for brivaracetam is latest...

UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annua...

UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annual Meeting PR...

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of...

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-6.82	-6.47550322826	105.32	106.28	90.34	16672	97.00375991	DR
4	0.94	0.963509635096	97.56	106.6	90.34	63361	98.53408402	DR
12	0.4	0.407747196738	98.1	106.6	90.34	36149	98.1222261	DR
26	9.17	10.265308407	89.33	106.6	86.71	26611	96.68279963	DR
52	39.582	67.1815065006	58.918	106.6	56.77	22880	86.04425972	DR
156	43.93	80.502107385	54.57	106.6	32.82	21908	56.73384023	DR
260	59.47	152.369971817	39.03	106.6	32.45	21153	55.92303045	DR

UCBJY - Frequently Asked Questions (FAQ)

What is the current UCB (PK) share price?

The current share price of UCB (PK) is US$ 98,50

How many UCB (PK) shares are in issue?

UCB (PK) has 379.189.796 shares in issue

What is the market cap of UCB (PK)?

The market capitalisation of UCB (PK) is USD 35,19B

What is the 1 year trading range for UCB (PK) share price?

UCB (PK) has traded in the range of US$ 56,77 to US$ 106,60 during the past year

What is the PE ratio of UCB (PK)?

The price to earnings ratio of UCB (PK) is 64,44

What is the cash to sales ratio of UCB (PK)?

The cash to sales ratio of UCB (PK) is 12,23

What is the reporting currency for UCB (PK)?

UCB (PK) reports financial results in EUR

What is the latest annual turnover for UCB (PK)?

The latest annual turnover of UCB (PK) is EUR 5,61B

What is the latest annual profit for UCB (PK)?

The latest annual profit of UCB (PK) is EUR 1,07B

What is the registered address of UCB (PK)?

The registered address for UCB (PK) is 60, ALLEE DE LA RECHERCHE, BRUSSELS, BRUSSELS-CAPITAL REGION, B-1070

What is the UCB (PK) website address?

The website address for UCB (PK) is www.ucb.com

Which industry sector does UCB (PK) operate in?

UCB (PK) operates in the CHEMICALS & ALLIED PRODUCTS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
SHWZMedicine Man Technologies Inc (CE)	US$ 0,01 (999.900,00%)	1,2k
GENNGenesis Healthcare Inc (CE)	US$ 0,0002 (19.900,00%)	938
BLSPBlue Sphere Corporation (CE)	US$ 0,0001 (9.900,00%)	326,91k
BIMIBIMI International Medical Inc (CE)	US$ 0,01 (9.900,00%)	5k
NBRVFNabriva Therapeutics PLC (CE)	US$ 0,01 (9.900,00%)	1,18k
BETSFBit Brother Ltd (CE)	US$ 0,000001 (-99,99%)	302
NLVVFNew Leaf Ventures (CE)	US$ 0,000001 (-99,99%)	600
KLMRKLM Royal Dutch Airlines (CE)	US$ 0,0003 (-99,85%)	180
MTEMMolecular Templates Inc (CE)	US$ 0,000001 (-99,80%)	400
SRUTFSproutly Canada Inc (CE)	US$ 0,000001 (-99,50%)	7k
HMBLHUMBL Inc (PK)	US$ 0,00035 (-12,50%)	409,38M
GRLTGrillit Inc (PK)	US$ 0,0011 (83,33%)	175,75M
DPLSDarkPulse Inc (PK)	US$ 0,0003 (0,00%)	126,35M
RONNRonn Motor Group Inc (PK)	US$ 0,0001 (-50,00%)	119,29M
AITXArtificial Intelligence Technology Solutions Inc (PK)	US$ 0,0023 (0,00%)	114,49M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

UCB (PK) (UCBJY)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über UCB (PK)

UCBJY Neueste Nachrichten

UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services

New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S.

UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015

UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam

UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annua...

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of...

UCB, Georgia Institute of Technology Partner to Harness the Power of Predictive Analytics in Epilepsy Care

UCB reinforces its leadership in epilepsy at the 2014 Annual Meeting of the American Epilepsy Society (AES)

UCB shows strong scientific presence at leading rheumatology meeting

Advent International and Avista Capital Partners to Acquire Kremers Urban Pharmaceuticals from UCB

UCBJY - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

UCB (PK) (UCBJY) Börsenkurse

UCB (PK) (UCBJY)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über UCB (PK)

UCBJY Neueste Nachrichten

UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services

New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S.

UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015

UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam

UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annua...

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of...

UCB, Georgia Institute of Technology Partner to Harness the Power of Predictive Analytics in Epilepsy Care

UCB reinforces its leadership in epilepsy at the 2014 Annual Meeting of the American Epilepsy Society (AES)

UCB shows strong scientific presence at leading rheumatology meeting

Advent International and Avista Capital Partners to Acquire Kremers Urban Pharmaceuticals from UCB

UCBJY - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen